guest ::
| Home > Publications database > SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes. > print |
| Home > Publications database > SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes. > print |
| 001 | 178754 | ||
| 005 | 20240229143555.0 | ||
| 024 | 7 | _ | |a 10.1016/j.radonc.2022.01.038 |2 doi |
| 024 | 7 | _ | |a pmid:35121031 |2 pmid |
| 024 | 7 | _ | |a 0167-8140 |2 ISSN |
| 024 | 7 | _ | |a 1879-0887 |2 ISSN |
| 024 | 7 | _ | |a altmetric:121960605 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-00249 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Regnery, Sebastian |0 P:(DE-He78)f4c0be14a7bb58948e5800ccdcbfe9bc |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2022 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1645450801_26140 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:E050#LA:E050# / Volume 168, March 2022, Pages 106-112 |
| 520 | _ | _ | |a To demonstrate dosimetry benefits and report clinical outcomes of stereotactic magnetic resonance (MR)-guided online adaptive radiotherapy (SMART) of abdominopelvic lymphatic oligometastases.Prospective registry data of 26 patients with 31 oligoprogressive lymphatic metastases (1 - 2 lesions) who received SMART between April 2020 and April 2021 was analyzed. Prostate cancer was the most common histology (69%). Most patients (63%) had received previous abdominopelvic radiotherapy (RT). SMART was delivered in 3 - 7 fractions based on planning target volume (PTV) location and previous dose exposures. For SMART, the baseline plan was recalculated on daily 3D MR-imaging (predicted plan), and plan adaptation was mandatory in case of planning objective violations.Plan adaptation was mostly performed due to violation of planning objectives in the predicted plan (134/140 fractions, 96%) and significantly improved plan dosimetry: 1) PTV coverage was increased (predicted: median 89%, adapted: median 95%, p < 0.001), 2) organs-at-risk (OAR) overdoses were reduced (predicted: 27/140 (19%), adapted: 1/140 (1%), p < 0.001) and 3) PTV overdoses were reduced (predicted: 21/140 (15%), adapted: 1/140 (1%), p < 0.001). After a median follow-up of 9.8 months, one patient had in-field tumor progression and twelve patients had out-field tumor progression (at 6 months: progression-free survival: 63% [46 - 88%], local control rate: 97% [90 - 100%]). Treatment was tolerated well and no grade ≥ 3 toxicity was reported.SMART improves target volume coverage and yields superior OAR protection compared to non-adaptive radiotherapy, thus representing an innovative approach to challenging cases, such as repeated radiotherapy. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |a Image-Guided Radiotherapy (IGRT) |2 Other |
| 650 | _ | 7 | |a Lymphatic Metastasis |2 Other |
| 650 | _ | 7 | |a Magnetic Resonance Imaging (MRI) |2 Other |
| 650 | _ | 7 | |a Pelvic Neoplasms |2 Other |
| 650 | _ | 7 | |a Prostate Cancer |2 Other |
| 650 | _ | 7 | |a Stereotactic Body Radiotherapy (SBRT) |2 Other |
| 700 | 1 | _ | |a Buchele, Carolin |b 1 |
| 700 | 1 | _ | |a Piskorski, Lars |b 2 |
| 700 | 1 | _ | |a Weykamp, Fabian |b 3 |
| 700 | 1 | _ | |a Held, Thomas |b 4 |
| 700 | 1 | _ | |a Eichkorn, Tanja |b 5 |
| 700 | 1 | _ | |a Rippke, Carolin |b 6 |
| 700 | 1 | _ | |a Katharina Renkamp, C. |b 7 |
| 700 | 1 | _ | |a Klüter, Sebastian |b 8 |
| 700 | 1 | _ | |a Ristau, Jonas |b 9 |
| 700 | 1 | _ | |a König, Laila |b 10 |
| 700 | 1 | _ | |a Koerber, Stefan A |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Adeberg, Sebastian |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Debus, Jürgen |0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |b 13 |u dkfz |
| 700 | 1 | _ | |a Hörner-Rieber, Juliane |0 P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0 |b 14 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.radonc.2022.01.038 |g p. S0167814022000640 |0 PERI:(DE-600)1500707-8 |p 106-112 |t Radiotherapy and oncology |v 168 |y 2022 |x 0167-8140 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:178754 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)f4c0be14a7bb58948e5800ccdcbfe9bc |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-31 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-31 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-29 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-29 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b RADIOTHER ONCOL : 2021 |d 2022-11-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-29 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-29 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b RADIOTHER ONCOL : 2021 |d 2022-11-29 |
| 920 | 2 | _ | |0 I:(DE-He78)E050-20160331 |k E050 |l E050 KKE Strahlentherapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E050-20160331 |k E050 |l E050 KKE Strahlentherapie |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)E050-20160331 |k E050 |l E050 KKE Strahlentherapie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E050-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|